Results 81 to 90 of about 192,321 (310)

Prediction of Patient Drug Response via 3D Bioprinted Gastric Cancer Model Utilized Patient‐Derived Tissue Laden Tissue‐Specific Bioink

Advanced Science
Despite significant research progress, tumor heterogeneity remains elusive, and its complexity poses a barrier to anticancer drug discovery and cancer treatment.
Yoo‐mi Choi, Deukchae Na, Goeun Yoon, Jisoo Kim, Seoyeon Min, Hee‐Gyeong Yi, Soo‐Jeong Cho, Jae Hee Cho, Charles Lee, Jinah Jang   +9 more
doaj   +1 more source

Transcriptional profiling of circulating extracellular vesicles from prebiopsy prostate cancer patients

Molecular Oncology, EarlyView.
RNA profiling of circulating extracellular vesicles (EVs) from blood samples of men undergoing prostate biopsy identifies transcripts associated with clinically significant prostate cancer. Integrative analysis with public tumor datasets links EV‐derived gene signatures to tumor stage and progression‐free survival, highlighting CASP3, XRCC2, and RIT1 ...
Stefan Werner, Pierre Tennstedt, Randi C. Pose, Christian Müller, Katharina Besler, Svenja Schneegans, Malik Alawi, Marie C. Roesch, Sven Peine, Desiree Bonci, Joanna Budna‐Tukan, Evi Lianidou, Catherine Alix‐Panabières, Derya Tilki, Klaus Pantel   +14 more
wiley   +1 more source

Utility of in vitro systems and preclinical data for the prediction of human intestinal first-pass metabolism during drug discovery and preclinical development [PDF]

, 2013
A growing awareness of the risks associated with extensive intestinal metabolism has triggered an interest in developing robust methods for its quantitative assessment.
Karlsson, Fredrik, Bouchene, Salim, Hilgendorf, Constanze,, Dolgos, Hugues, Karlsson, Fredrik,, Dolgos, Hugues,, Hilgendorf, Constanze, Peters, Sheila Annie, Bouchene, Salim,, Peters, Sheila Annie,   +9 more
core   +1 more source

Mechanism-based Preclinical Approaches for the Evaluation of Drug-Drug Interactions.

Drug Metabolism and Pharmacokinetics, 2000
Pharmacokinetic drug-drug interactions (PDDI), in which the pharmacokinetic clearance of one drug is altered by a co-administered drug, can be divided mechanistically into two general categories: 1. inhibitory PDDI, the inhibition of the metabolic clearance of one drug by a co-administered drug; and 2.
openaire   +2 more sources

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

In vitro studies and in vivo evaluation of novel diamidines for 2nd stage sleeping sickness [PDF]

, 2014
Summary: African sleeping sickness is one of the most neglected tropical diseases. Transmitted by the tsetse fly it exclusively occurs in sub-Saharan Africa.
Wenzler, Tanja
core   +1 more source

Mechanisms of Cell Death Induced by Cannabidiol Against Tumor Cells: A Review of Preclinical Studies

Plants
Commonly known as marijuana or hemp, Cannabis sativa L. (Cannabaceae), contains numerous active compounds, particularly cannabinoids, which have been extensively studied for their biological activities.
Edilene S. A. Melo, Estefani A. Asevedo, Joaquim Maurício Duarte-Almeida, Fahrul Nurkolis, Rony Abdi Syahputra, Moon Nyeo Park, Bonglee Kim, Renê Oliveira do Couto, Rosy Iara Maciel de A. Ribeiro   +8 more
doaj   +1 more source

Preclinical Models of Restenosis and Their Application in the Evaluation of Drug-Eluting Stent Systems [PDF]

Veterinary Pathology, 2009
Coronary arterial disease (CAD) is the leading cause of death in the United States, the European Union, and Canada. Percutaneous coronary intervention (PCI) has revolutionized the treatment of CAD, and it is the advent of drug-eluting stent (DES) systems that has effectively allayed much of the challenge of restenosis that has plagued the success of ...
openaire   +2 more sources

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

Molecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, Sachi Okawa, Masataka Taoka, Shunta Mori, Tomoka Nishimura, Takaaki Tanaka, Go Makimoto, Kiichiro Ninomiya, Kammei Rai, Eiki Ichihara, Ryohei Katayama, Katsuyuki Hotta, Masahiro Tabata, Yosuke Togashi, Yoshinobu Maeda, Martin L. Sos, Katsuyuki Kiura, Kadoaki Ohashi   +19 more
wiley   +1 more source

A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose‐driven glioblastoma

Molecular Oncology, EarlyView.
The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka, Wioleta Cieślik, Wojciech Płaziński, Katarzyna Stępnik, Anna Boguszewska‐Czubara, Elżbieta Kot, Robert Musioł, Mateusz Jasica, Anna Mrozek‐Wilczkiewicz, Katarzyna Malarz   +9 more
wiley   +1 more source